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1762and an increased risk for sudden
cardiac death (1,2). Over the past
decade, pathogenic ARVD/C-
associated mutations have been
identiﬁed in 5 desmosomal genes
(3–7), and clinical genetic testing
is now routinely performed (8).
Consequently, cardiologists will
be more often confronted with
the question of how to manage
asymptomatic mutation carriers.
Because familial ARVD/C is
a clinically heterogenous disor-
der with incomplete penetrance
and variable expressivity (9–11),management of mutation carriers remains challenging, and
the optimal approach to risk stratiﬁcation is yet to be
elucidated.
Current guidelines recommend serial screening of genet-
ically predisposed patients using a combination of electro-
cardiography, Holter monitoring, and imaging modalities
(12). Many studies have shown that electrocardiography
(13–15) and Holter monitoring (16) are useful in the risk
stratiﬁcation of patients with ARVD/C. Because of the
anatomical, functional, and tissue-speciﬁc characteristics of
ARVD/C, cardiac magnetic resonance (CMR) imaging is an
ideal technique for the diagnostic workup (17). The incre-
mental value and optimal timing of CMR in the prognostic
workup of mutation carriers, however, are not well deﬁned.
In patients with ARVD/C, both electrical uncoupling
(18–20) and altered tissue architecture (3,6,20) are thought
to contribute to arrhythmic propensity. We hypothesized
that mutation carriers with both electrical and structural
abnormalities on clinical evaluation are at particularly high
risk for developing life-threatening arrhythmias and that
CMR is a valuable tool to risk-stratify patients with
abnormal electrical baseline test results.
Through prospective follow-up of ARVD/C mutation
carriers with no histories of sustained ventricular arrhythmia,
we sought to identify the optimal role of CMR within a risk
stratiﬁcation paradigm in these patients. As a secondary
objective, we aimed to characterize the association between
abnormal electrical test results (electrocardiography and
Holter monitoring) and CMR abnormalities in ARVD/C
mutation carriers.Methods
Study population. The study population was identiﬁed
from the Johns Hopkins ARVD/C registry. The Johns
Hopkins ARVD/C registry, established in 1999, prospec-
tively enrolls patients and their family members referred to
the Johns Hopkins ARVD/C Center with possible histories
of this disease. Participants are contacted, and updated
medical records are collected annually. For the present study,
69 registry enrollees were included who: 1) harboredpathogenic ARVD/C-associated desmosomal mutations;
2) had no histories of sustained ventricular tachycardia (VT)
or ventricular ﬁbrillation at the time of enrollment; and
3) underwent CMR available for analysis. The majority
of study subjects (n ¼ 54 [78%]) were ﬁrst-degree relatives
of ARVD/C probands who were identiﬁed through family
screening. The remainder (n ¼ 15 [22%]) presented with
syncope (n ¼ 6), palpitations (n ¼ 3), or chest pain (n ¼ 1)
that was not associated with a documented arrhythmia;
5 were incidentally discovered during routine medical
examination. All registry participants provided written
informed consent, and the study protocol was approved by
the Johns Hopkins School of Medicine Institutional Review
Board.
Clinical electrical baseline testing. Participants were
evaluated as described previously (16,21). Medical records
for each patient were obtained at enrollment. For the
purpose of this study, 12-lead electrocardiograms and Holter
results closest to presentation were obtained and carefully
reviewed for the presence of electrical abnormalities per
revised task force criteria (TFC) (22) (Online Table 1).
All 69 patients underwent routine 12-lead electrocardi-
ography (recorded at rest, 10 mm/mV at a paper speed 25
mm/s). Electrocardiographic (ECG) results were classiﬁed
as abnormal when repolarization (precordial T-wave inver-
sion in leads V1 and V2 or beyond) and/or depolarization
(epsilon waves or terminal activation duration 55 ms)
criteria for ARVD/C were present. No patient was taking
antiarrhythmic or other medications known to affect the
QRS complex at the time of electrocardiography.
Overall, 54 patients (78%) underwent 24-h Holter
monitoring. The Holter monitor was analyzed for ventric-
ular ectopic activity, deﬁned as isolated premature ventricular
complexes exceeding 500 in 24 h and/or recorded runs of
nonsustained VT (3 consecutive premature beats at >100
beats/min).
Electrocardiography andHolter monitoring were combined
to obtain a composite measure of electrical abnormalities at
presentation. Any participant meeting at least 1 of the minor
ECG or Holter TFC (22) was considered to have evidence of
electrical abnormality.
CMR imaging. All 69 study participants underwent CMR,
performed according to standard protocols for ARVD/C,
which have previously been described in detail (23,24). All
images were acquired using a 1.5-T scanner with a phased-
array cardiac coil during breath-holds gated to the electro-
cardiogram. Cine images were acquired in axial and short-axis
planes covering the entire right and left ventricles with
a steady-state free precession technique. Fast spin echo (both
fat-suppressed and non-fat-suppressed) images were acquired
in both axial and short-axis planes with double inversion
recovery blood suppression pulses. A gadolinium-based con-
trast agent was administered intravenously, and contrast-
enhanced images were acquired on average 10 minutes after
contrast administration using a phase-sensitive inversion
recovery sequence in both axial and short-axis planes.
Table 1 Patient Characteristics
Variable
Overall
(n ¼ 69)
Normal Electrical
Baseline Test Results
(n ¼ 27)
Abnormal Electrical
Baseline Test Results
(n ¼ 42) p Value
Men 29 (42%) 12 (44%) 17 (40%) NS
Follow-up (yrs) 5.8  4.4 7.0  4.2 5.1  4.5 NS
Age at presentation (yrs) 27.0  15.3 24.2  16.7 28.8  14.2 NS
Symptomatic at presentation 22 (32%) 3 (11%) 19 (45%) 0.003
Syncope 9 (13%) 0 (0%) 9 (21%) 0.010
Presyncope 6 (9%) 0 (0%) 6 (14%) 0.040
Palpitations 16 (23%) 3 (11%) 13 (31%) NS
Chest pain 3 (4%) 0 (0%) 3 (7%) NS
ICD implantation during follow-up 26 (38%) 2 (7%) 24 (57%) <0.001
Age at implantation (yrs) 29.7  12.6 47.1  10.5 28.1  11.8 NS
Values are n (%) or mean  SD.
ICD ¼ implantable cardioverter-deﬁbrillator.
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TFC (22), deﬁned as the presence of an RV regional wall
motion abnormality (akinesia, dyskinesia, or dyssynchronous
contraction) combinedwith enlargedRV end-diastolic volume
(100 ml/m2 in men and 90 ml/m2 in women) and/or
reduced RV ejection fraction (45%) (Online Table 1).
CMR analysis was based on consensus agreement of
radiologists with special interest in ARVD/C, who were
blinded to all clinical data of included patients. CMR results
were classiﬁed as abnormal if at least a minor task force
criterion for ARVD/C was present. Additionally, the CMR
analysts ascertained the presence of qualitative ﬁndings that
were previously associated with ARVD/C (fatty inﬁltration
and delayed gadolinium enhancement, as well as left
ventricular involvement).
Follow-up and outcome measure. Patient management
was performed at the discretion of the treating physi-
cian. According to ARVD/C registry protocol, patients
were prospectively followed at yearly intervals. The pri-
mary outcome measure was the occurrence of a sustained
ventricular arrhythmia (a composite measure of the occur-
rence of spontaneous sustained VT, aborted sudden cardiac
death, sudden cardiac death, or appropriate implantableTable 2
Electrical Baseline Test Results in ARVD/C Mutation
Carriers Without Prior Ventricular Arrhythmia
Abnormal ECG results 39 (57)
Negative T waves in leads V1 and V2 7 (10)
Negative T waves leads V1 to V3 or beyond 28 (41)
Negative T waves in leads V4 to V6 in the presence of RBBB 0 (0)
Epsilon waves 1 (1)
Terminal activation duration 55 ms 13 (19)
Abnormal results on Holter monitoring* 14 (26)
>500 PVCs/24 h 13 (24)
Nonsustained VT recorded 9 (17)
Electrical abnormalitiesy 42 (61)
Values are n (%). *Fifty-four patients underwent Holter monitoring. yDeﬁned as the presence of 1
abnormal ECG and/or Holter monitoring parameter.
ARVD/C ¼ arrhythmogenic right ventricular dysplasia/cardiomyopathy; ECG ¼ electrocardio-
graphic; PVC ¼ premature ventricular complex; RBBB ¼ right bundle branch block; VT ¼ ventricular
tachycardia.cardioverter-deﬁbrillator (ICD) intervention for a ventricular
arrhythmia; deﬁnitions are provided in Online Table 2). In
patients without ICDs, the primary outcome was adjudi-
cated on the basis of reviewing electrocardiograms and
medical records; in patients with ICDs, the device-stored
electrocardiograms were reviewed for the appropriateness
of ICD therapy. In patients with multiple endpoints, the
ﬁrst event was considered the censoring event.
Statistical analysis. All continuous data are expressed as
mean  SD and categorical variables as number (percent).
Continuous variables were compared using independent
Student t tests or Mann-Whitney U tests and categorical
data using chi-square or Fisher exact tests. Cumulative
freedom from the composite arrhythmic outcome since
presentation was determined using the Kaplan-Meier
method. Differences in survival among groups were evalu-
ated using a log-rank test. A p value <0.05 was considered
signiﬁcant. Statistical calculations were performed using
SPSS version 19.0 (IBM, Chicago, Illinois).Results
Clinical characterization. The study population comprised
69 patients from 40 families who were identiﬁed as
harboring pathogenic ARVD/C-associated desmosomal
mutations (83% plakophilin-2) (Online Table 3).
Characteristics of study participants are shown in Table 1.
Mean age at presentation was 27.0  15.3 years, and 42%
were men. Of 69 subjects, 47 (68%) were asymptomatic at
presentation; the remainder (n ¼ 22 [32%]) had histories of
syncope, presyncope, palpitations, or chest pain.
Overall, 42 patients (61%) had abnormal baseline electrical
test results, deﬁned as at least 1 minor criterion for ARVD/C
on the basis of evaluation of ECG and Holter monitoring
results (Table 2). In the total cohort, abnormal ECG
results were observed in 39 patients (57%), and abnormal
Holter ﬁndings were observed in 14 of 54 patients (26%).
Overall, 35 patients (51%) fulﬁlled repolarization criteria for
ARVD/C (28 major and 7 minor), 13 patients (19%) fulﬁlled
depolarization criteria for ARVD/C (1 major and 12 minor),
Figure 1 Patient Flowchart
Patient ﬂowchart showing prognostic workup and arrhythmic events in the study
population. CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiography.
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ARVD/C (all minor criteria). ICDs were implanted in 26
patients (38%), of whom the majority (n ¼ 24 [92%]) had
abnormal ECG and/or Holter results at baseline (Table 1).
Prognostic workup for the study population is shown in
Figure 1.
CMR ﬁndings. Structural and functional CMR abnor-
malities in the entire cohort are summarized in Table 3.
Overall, 21 patients (30%) had abnormal CMR results ful-
ﬁlling TFC for ARVD/C. The majority of patients with
abnormal CMR results fulﬁlled major TFC (17 of 21
patients [81%]). Symptomatic patients were signiﬁcantly
more likely to fulﬁll TFC for CMR than asymptomatic
patients (14 [64%] patients vs. 7 [15%] patients, p < 0.001).
The mean time between presentation and CMR was 3.4 
3.9 years. There was no statistically signiﬁcant difference in
age at CMR for patients with normal versus abnormal CMR
results (31.5  16.6 years vs. 28.0  11.7 years, p ¼ NS).
Compared with patients with normal electrical baseline
test results, those with electrical abnormalities on the basis
of ECG and Holter evaluation were signiﬁcantly more
likely to have abnormal CMR results (20 [48%] patients vs.
1 [4%] patient, p < 0.001), with higher RV volumes and
lower biventricular ejection fractions (Table 3). The only
patient with normal electrical test results and abnormal
CMR results had dyskinesia of the RV free wall and a mildly
diminished RV ejection fraction (45%), fulﬁlling a minor
task force criterion on CMR. This patient had isolated
T-wave inversions in leads V1 and V3 on electrocardiog-
raphy (Online Fig. 1) and 20 premature ventricularcomplexes on 24-h Holter monitoring, thus not fulﬁlling
TFC for electrocardiography or Holter monitoring.
Arrhythmic outcomes. Over a mean follow-up period
of 5.8  4.4 years, 11 patients (16%) experienced sus-
tained ventricular arrhythmias. Characteristics of patients
experiencing arrhythmic events are shown in Table 4. Of 11
patients experiencing events, the majority were men and
probands (both n¼ 8 [73%]). Themean age at ﬁrst arrhythmic
eventwas 25.2 5.0 years (range: 17 to 32 years), and themean
cycle length of the event was 258  42 ms (range: 188 to 323
ms). For 7 patients (64%), the ﬁrst arrhythmic event was an
appropriate ICD intervention; 4 patients had spontaneous VT
or ventricular ﬁbrillation. The cycle length of the tachyar-
rhythmia was similar for patients who experienced ICD
interventions and thosewith spontaneous episodes of sustained
VT or ventricular ﬁbrillation (260  37 ms vs. 255  57 ms,
respectively, p ¼ NS). ICD details are provided in Online
Table 4. ICD programming was not signiﬁcantly different
between ICD carriers with and without appropriate interven-
tion (mean rate cutoffs 189  12 beats/min and 191  15
beats/min, respectively, p¼NS).None of the study population
required cardiac transplantation or died during follow-up.
All patients with arrhythmic events presented with elec-
trical abnormalities (Fig. 2). Mean time between presenta-
tion and the arrhythmic event was 4.5  4.3 years (range:
0.2 to 14.0 years). For both electrocardiography and Holter
monitoring separately, event-free survival was signiﬁcantly
lower in patients with abnormal test results compared with
those with normal test results (p ¼ 0.001 and p ¼ 0.002,
respectively). Overall, event-free survival in patients with
any electrical abnormality (on electrocardiography and/or
Holter monitoring) was signiﬁcantly lower than survival
in patients without electrical abnormalities (p ¼ 0.001).
Among patients with electrical abnormalities, cumulative
survival free from arrhythmic events after 1, 5, and 10 years
was 95% (95% conﬁdence interval [CI]: 87% to 100%), 76%
(95% CI: 60% to 92%), and 66% (95% CI: 46% to 86%),
respectively.
Sustained ventricular arrhythmias occurred exclusively in
patients with abnormal CMR results (Fig. 3). All patients with
arrhythmic events fulﬁlled a major task force criterion
for CMR. Biventricular involvement was seen in 7 of 11
patients (64%) experiencing sustained tachyarrhythmias.
Compared with patients with electrical abnormalities in
isolation (n ¼ 22), patients with both electrical and CMR
abnormalities (n ¼ 20) had a signiﬁcantly higher propensity
toward ventricular arrhythmia (p < 0.001). In this group,
cumulative survival free from arrhythmic events after 1, 5, and
10 years was 89% (95%CI: 75% to 100%), 54% (95%CI: 29%
to 79%), and 36% (95% CI: 9% to 63%), respectively.
Discussion
During the past decade, understanding of the genetic basis
of ARVD/C has evolved greatly (3–7). Genetic screening of
patients with ARVD/C identiﬁes pathogenic mutations in
Table 3 Quantitative and Qualitative CMR Findings in the Study Population
Variable
Overall
(n ¼ 69)
Normal Electrical
Baseline Test Results
(n ¼ 27)
Abnormal Electrical
Baseline Test Results
(n ¼ 42) p Value
Fulﬁllment of TFC for CMR 21 (30%) 1 (4%) 20 (48%) <0.001
Major criterion 17 (25%) 0 (0%) 17 (41%) <0.001
Minor criterion 4 (6%) 1 (4%) 3 (7%) NS
Quantitative parameters
RV EDV/BSA (ml/m2) 84.5  21.2 77.6  16.1 90.6  24.0 0.012
RV ESV/BSA (ml/m2) 46.0  18.7 37.3  8.7 52.6  22.5 0.006
RV EF (%) 47.2  10.1 52.0  5.2 43.2  11.9 0.002
LV EDV/BSA (ml/m2) 80.2  14.9 76.2  14.5 82.3  14.7 NS
LV ESV/BSA (ml/m2) 37.4  10.2 32.7  8.1 40.2  10.5 0.004
LV EF (%) 53.8  6.8 57.7  4.6 51.4  6.7 <0.001
LV EDV/RV EDV 0.97  0.17 0.99  0.07 0.95  0.20 NS
Qualitative parameters
Global RV dilation 16 (23%) 0 (0%) 16 (38%) <0.001
Global RV hypokinesia 12 (17%) 0 (0%) 12 (29%) 0.002
Global LV dilation 2 (3%) 0 (0%) 2 (5%) NS
Global LV hypokinesia 4 (6%) 0 (0%) 4 (10%) NS
RV regional wall motion abnormalities 24 (35%) 3 (11%) 21 (50%) 0.001
RV regional aneurysm 6 (9%) 1 (4%) 5 (12%) NS
RV regional fatty inﬁltration 9/68 (13%) 1/27 (4%) 8/41 (20%) NS
RV regional delayed enhancement 2/61 (3%) 0/24 (0%) 2/37 (5%) NS
LV regional wall motion abnormalities 6 (9%) 0 (0%) 6 (14%) 0.040
LV regional aneurysm 0 (0%) 0 (0%) 0 (0%) d
LV regional fatty inﬁltration 13 (19%) 1 (4%) 12 (29%) 0.010
LV regional delayed enhancement 7/61 (11%) 1/24 (4%) 6/37 (16%) NS
Involvement
RV involvement only 12 (17%) 2 (7%) 10 (24%) NS
LV involvement only 3 (4%) 1 (4%) 2 (5%) NS
Biventricular involvement 15 (22%) 1 (4%) 14 (33%) 0.004
Values are n (%), mean  SD, or n/N (%).
BSA ¼ body surface area; CMR ¼ cardiac magnetic resonance; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end-systolic volume; LV ¼ left
ventricular; RV ¼ right ventricular; TFC ¼ task force criteria.
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1765approximately one-half of individuals (8–10,25–27). Once
a pathogenic mutation is identiﬁed in a proband, down-
stream genetic testing of family members is recommended
(12,26). Although many studies have assessed noninvasive
modalities for risk stratiﬁcation in patients with ARVD/C
(13,14,16,28–30), several uncertainties remain in the evalua-
tion and management of these patients. For example, it is
unclear what minimal initial testing should be performed in
mutation-positive patients. Although conventional wisdom
suggests that patients at risk for developing ARVD/C on the
basis of the presence of a pathogenic mutation should
undergo complete ARVD/C screening, including CMR,
at regular intervals, there is little objective evidence to de-
monstrate the necessity of this approach. Also, with regard
to CMR, it is important to recognize that many imaging
centers have little or no experience with clinical evaluation of
ARVD/C and that nonspeciﬁc ﬁndings such as fatty inﬁltra-
tion alone or minor wall motion abnormalities are often over-
interpreted as providing evidence of ARVD/C (17,31–34).
Our study provides data that help address some of the clinically
important questions relating to ARVD/C mutation carriers
without histories of prior arrhythmic events.Electrical abnormalities on electrocardiography and
Holter monitoring. An important ﬁnding of this study
is that ARVD/C mutation carriers who lack electrical
abnormalities on ECG and Holter monitor evaluation have
a very low risk for arrhythmia during a mean follow-up
period of 7 years. These data suggest that the presence of
a mutation itself does not necessarily confer risk for
arrhythmia in these patients. These data are also in align-
ment with prior retrospective studies, which have shown
that electrocardiography (13–15) and Holter monitoring
(16) are useful tools in the risk stratiﬁcation of patients with
ARVD/C. Although included in the revised TFC, we did
not use signal-averaged electrocardiography to deﬁne elec-
trical abnormalities. In our cohort, signal-averaged ECG
data were available in only a subset of patients, in whom they
did not add to the risk stratiﬁcation paradigm.
We determined electrical abnormalities based on the
ECG and Holter examinations closest to presentation. It is
possible that some of the patients with normal results on
electrocardiography and Holter monitoring at presentation
developed electrical changes during their clinical courses;
however, this was not speciﬁcally investigated in our study.
Table 4 Characteristics of Patients According to Arrhythmic Outcomes
Variable
No Arrhythmic Event
(n ¼ 58)
Arrhythmic Event
(n ¼ 11) p Value
Men 21 (36%) 8 (73%) 0.024
Proband 7 (12%) 8 (73%) <0.001
Symptomatic at presentation 15 (26%) 7 (64%) 0.014
Syncope 7 (12%) 2 (18%) NS
Presyncope 4 (7%) 2 (18%) NS
Palpitations 10 (17%) 6 (55%) 0.007
Chest pain 2 (3%) 1 (9%) NS
Abnormal results on ECG 29 (50%) 10 (91%) 0.012
Negative T waves in leads V1 and V2 6 (10%) 1 (9%) NS
Negative T waves in leads V1 to V3 or beyond 19 (33%) 9 (82%) 0.002
Epsilon waves 0 (0%) 1 (9%) 0.021
Terminal activation duration 55 ms 9 (16%) 4 (36%) NS
Abnormal results on Holter monitoring* 10/49 (20%) 4/5 (80%) 0.004
>500 PVCs/24 h 9/49 (18%) 4/5 (80%) 0.002
Nonsustained VT recorded 6/49 (12%) 3/5 (60%) 0.006
Fulﬁllment of TFC for CMR 10 (17%) 11 (100%) <0.001
Major TFC 6 (10%) 11 (100%) <0.001
Minor TFC 4 (7%) 0 (0%) NS
RV EDV/BSA (ml/m2) 80.9  19.2 109.9  20.7 <0.001
LV EDV/BSA (ml/m2) 78.6  13.9 87.7  17.6 NS
RV EF (%) 49.3  9.2 32.6  6.8 <0.001
LV EF (%) 55.2  6.0 45.8  4.9 <0.001
RV wall motion abnormalities 14 (24%) 11 (100%) <0.001
RV fatty inﬁltration 7 (12%) 2 (20%) NS
RV delayed enhancementy 0/52 (0%) 2/9 (22%) 0.001
LV wall motion abnormalities 4 (7%) 2 (18%) NS
LV fatty inﬁltration 7 (12%) 6 (55%) 0.001
LV delayed enhancementy 5/52 (10%) 2/9 (22%) NS
RV involvement only 8 (14%) 4 (36%) NS
LV involvement only 3 (5%) 0 (0%) NS
Biventricular involvement 8 (14%) 7 (64%) <0.001
Values are n (%) or mean  SD. *54 patients underwent Holter monitoring. yFor 61 patients, delayed enhancement images were available.
Abbreviations as in Tables 2 and 3.
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without electrical abnormalities at baseline do not have
disease expression and therefore have no long-term risk
for arrhythmia; or 2) the more likely possibility that
ARVD/C mutation carriers without electrical abnormalities
are in the concealed phase of the disease before overt disease
manifestation. The fact that none of the patients without
electrical abnormalities developed sustained ventricular
arrhythmias during almost 6 years of follow-up suggests that
there may be a long latent concealed phase in most patients.
It is important to note in this regard that we routinely advise
mutation carriers to give up high-level athletics. It is
certainly possible that the absence of arrhythmic events in
patients with an initially negative electrical and CMR results
may not be applicable to ARVD/Cmutation carriers who do
not restrict athletic activity.
Correlation of electrocardiography and Holter monitoring
with CMR. The second important result of our study is the
very low incidence of abnormal CMR results in patients
with normal results on electrocardiography and Holtermonitoring at baseline. Interestingly, only 1 patient in the
cohort fulﬁlled a minor task force criterion for CMR in the
absence of electrical abnormalities at presentation. It
is important to note that the ECG results in this patient
were abnormal, with T-wave inversion in leads V1 and V3
but not lead V2. Because T-wave inversion was not seen in
consecutive precordial leads, TFC for ARVD/C were not
fulﬁlled, and ECG results were classiﬁed as normal. It is also
important to note that this patient, with an atypical ECG
pattern and minor CMR abnormalities, did not experience
an arrhythmic event during follow-up. These data lead us
to believe that electrical abnormalities precede detectable
structural changes in ARVD/C and that evaluation of
cardiac structure and function using CMR may not be
necessary in the absence of baseline electrical abnormalities.
New CMR sequences such as high-resolution T1 mapping
are promising tools to detect early, subtle changes in the
right ventricle.
Arrhythmic events. The ﬁnal important result of our study
is that arrhythmic events occurred exclusively in patients
Figure 2 Risk for Sustained Ventricular Arrhythmias on the Basis of ECG and Holter Monitoring
Cumulative survival free from sustained ventricular arrhythmias among patients stratiﬁed according to the results of electrocardiography (ECG) (A) and Holter monitoring (B).
Event-free survival in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) mutation carriers who fulﬁlled at least 1 minor task force criterion for ARVD/C on ECG
and/or Holter monitoring was signiﬁcantly lower than survival in patients without electrical abnormalities.
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1767who met both electrical (ECG and/or Holter monitoring)
and structural (CMR) criteria for ARVD/C, suggesting that
an abnormal electrical and structural substrate is required for
arrhythmic occurrence. Our observation that patients with
electrical abnormalities in isolation had a low risk for
arrhythmic events in our study during 6 years of follow-up
opens the path for the strategic implementation of CMR
in patients with abnormal electrical baseline test results. This
insight is critically important, because CMR might be able
to identify those who may beneﬁt from intensive screening,
further clinical investigation, and consideration of prophy-
lactic ICD implantation.
Strategic use of CMR. Our study reveals the potential of
CMR to identify desmosomal mutation carriers at high risk
for arrhythmias, when used strategically in conjunction
with the results of electrocardiography and Holter moni-
toring. Prior work by our group has demonstrated the
utility of electrocardiography and Holter monitoring in
the risk stratiﬁcation of mutation carriers and highlighted
the increased arrhythmic risk of probands compared with
family members detected through cascade screening (15).
In the present study, 8 of 11 patients (73%) experiencing
arrhythmic events were probands, similar to prior ﬁndings.
The present study builds on this risk stratiﬁcation paradigm
and suggests a strategy for optimizing the use of CMR to
evaluate mutation carriers presenting without histories of
arrhythmic events. On the basis of our results, the optimal
approach would be to use CMR in patients with abnormal
results on electrocardiography and/or 24-h Holter moni-
toring at initial evaluation. Evaluation of cardiac structureand function using CMR may be able to be deferred in the
absence of baseline electrical abnormalities, at least among
asymptomatic family members detected through cascade
screening. The clinical follow-up evaluation of patients
who have no electrical abnormalities at baseline and those
who meet electrical criteria but do not have CMR ab-
normalities remains to be determined. Although further
studies are needed to validate our data, these results suggest
a strategy to optimize the use of CMR to detect ARVD/C-
associated mutation carriers who are at signiﬁcant risk for
arrhythmic events, while limiting the use of this second-
line test among those who are unlikely to derive beneﬁt
from its results.
Study limitations. Rate cutoff for therapy during ICD
programming was not uniform. However, ICD program-
ming was not different between ICD carriers with and
without interventions, and ICD discharges were adjudicated
as appropriate on the basis of ECG analyses. Studies of
ARVD/C, in particular involving CMR, are typically small.
Larger studies are needed to validate our ﬁndings and to
determine optimal clinical follow-up recommendations for
these high-risk patients. Also, our study sample was un-
derpowered to assess the independent prognostic value of
speciﬁc parameters. However, to our knowledge, we studied
the largest cohort of asymptomatic ARVD/C mutation
carriers using an integrated approach of both electrical and
CMR investigations. This provided us with the unique
possibility to assess the optimal role of CMR within the
prognostic workup of these patients. The only imaging
modality we used to deﬁne structural and/or functional
Figure 3
Incremental Risk for Sustained Ventricular
Arrhythmias With Abnormal CMR Results
Mutation carriers who met both electrical (electrocardiographic and/or Holter
monitoring) and cardiac magnetic resonance (CMR) criteria for arrhythmogenic
right ventricular dysplasia/cardiomyopathy had signiﬁcantly higher arrhythmic
propensity compared with patients with abnormal results on electrocardiography
and/or Holter monitoring in isolation. MRI ¼ magnetic resonance imaging; TFC ¼
task force criteria.
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1768abnormalities was CMR. Yet, because CMR offers the
unique possibility to assess cardiac morphologic, functional,
and tissue characteristics in a single investigation, it is
frequently used in the prognostic evaluation of ARVD/C
mutation carriers. In our study, CMR was not performed at
the time of initial presentation for all study participants.
This represents clinical practice, in which CMR is often not
considered a ﬁrst-line test for ARVD/C. Our study results
actually favor this approach, because all events occurred in
patients with abnormalities detected on their electrical
baseline tests, and electrical abnormalities appear to precede
abnormal CMR ﬁndings. It would be interesting to see
whether similar results can be obtained using echocardiog-
raphy or angiography.Conclusions
In this prospective cohort of 69 ARVD/C-associated path-
ogenic mutation carriers without prior sustained ventricular
arrhythmias, we demonstrate that there is a strong associa-
tion between electrical baseline abnormalities on electro-
cardiography and Holter monitoring and structural and
functional abnormalities detected by CMR. Importantly,
we show that CMR is a valuable tool to identify patients at
high risk for ventricular arrhythmias, especially when used
strategically in patients with abnormal electrical baseline test
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APPENDIX
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